vs
Essex Property Trust（ESS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Essex Property Trust的1.6倍（$772.1M vs $479.6M），Essex Property Trust净利率更高（17.9% vs 12.7%，领先5.1%），Revvity同比增速更快（5.9% vs 5.5%），过去两年Revvity的营收复合增速更高（9.0% vs 6.0%）
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ESS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$479.6M
营收增速更快
RVTY
高出0.3%
5.5%
净利率更高
ESS
高出5.1%
12.7%
两年增速更快
RVTY
近两年复合增速
6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $479.6M | $772.1M |
| 净利润 | $85.7M | $98.4M |
| 毛利率 | 70.0% | — |
| 营业利润率 | 31.7% | 14.5% |
| 净利率 | 17.9% | 12.7% |
| 营收同比 | 5.5% | 5.9% |
| 净利润同比 | -71.6% | 3.9% |
| 每股收益（稀释后） | $1.24 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESSRVTY
| Q4 25 | $479.6M | $772.1M | ||
| Q3 25 | $473.3M | $698.9M | ||
| Q2 25 | $469.8M | $720.3M | ||
| Q1 25 | $464.6M | $664.8M | ||
| Q4 24 | $454.5M | $729.4M | ||
| Q3 24 | $450.7M | $684.0M | ||
| Q2 24 | $442.4M | $691.7M | ||
| Q1 24 | $426.9M | $649.9M |
净利润ESSRVTY
| Q4 25 | $85.7M | $98.4M | ||
| Q3 25 | $172.7M | $46.7M | ||
| Q2 25 | $231.5M | $53.9M | ||
| Q1 25 | $212.8M | $42.2M | ||
| Q4 24 | $301.7M | $94.6M | ||
| Q3 24 | $125.5M | $94.4M | ||
| Q2 24 | $99.0M | $55.4M | ||
| Q1 24 | $285.1M | $26.0M |
毛利率ESSRVTY
| Q4 25 | 70.0% | — | ||
| Q3 25 | 69.2% | 53.6% | ||
| Q2 25 | 70.7% | 54.5% | ||
| Q1 25 | 69.6% | 56.5% | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.5% | 56.3% | ||
| Q2 24 | 70.8% | 55.7% | ||
| Q1 24 | 69.7% | 54.6% |
营业利润率ESSRVTY
| Q4 25 | 31.7% | 14.5% | ||
| Q3 25 | 44.5% | 11.7% | ||
| Q2 25 | 59.5% | 12.6% | ||
| Q1 25 | 55.3% | 10.9% | ||
| Q4 24 | 67.0% | 16.3% | ||
| Q3 24 | 28.6% | 14.3% | ||
| Q2 24 | 31.1% | 12.4% | ||
| Q1 24 | 31.0% | 6.8% |
净利率ESSRVTY
| Q4 25 | 17.9% | 12.7% | ||
| Q3 25 | 36.5% | 6.7% | ||
| Q2 25 | 49.3% | 7.5% | ||
| Q1 25 | 45.8% | 6.4% | ||
| Q4 24 | 66.4% | 13.0% | ||
| Q3 24 | 27.8% | 13.8% | ||
| Q2 24 | 22.4% | 8.0% | ||
| Q1 24 | 66.8% | 4.0% |
每股收益（稀释后）ESSRVTY
| Q4 25 | $1.24 | $0.86 | ||
| Q3 25 | $2.56 | $0.40 | ||
| Q2 25 | $3.44 | $0.46 | ||
| Q1 25 | $3.16 | $0.35 | ||
| Q4 24 | $4.00 | $0.77 | ||
| Q3 24 | $1.84 | $0.77 | ||
| Q2 24 | $1.45 | $0.45 | ||
| Q1 24 | $4.25 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $76.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.5B | $7.3B |
| 总资产 | $13.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESSRVTY
| Q4 25 | $76.2M | $919.9M | ||
| Q3 25 | $66.0M | $931.4M | ||
| Q2 25 | $58.7M | $991.8M | ||
| Q1 25 | $98.7M | $1.1B | ||
| Q4 24 | $66.8M | $1.2B | ||
| Q3 24 | $71.3M | $1.2B | ||
| Q2 24 | $55.2M | $2.0B | ||
| Q1 24 | $499.0M | $1.7B |
总债务ESSRVTY
| Q4 25 | — | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.6B | — |
股东权益ESSRVTY
| Q4 25 | $5.5B | $7.3B | ||
| Q3 25 | $5.6B | $7.4B | ||
| Q2 25 | $5.6B | $7.6B | ||
| Q1 25 | $5.6B | $7.6B | ||
| Q4 24 | $5.5B | $7.7B | ||
| Q3 24 | $5.4B | $7.9B | ||
| Q2 24 | $5.5B | $7.9B | ||
| Q1 24 | $5.5B | $7.8B |
总资产ESSRVTY
| Q4 25 | $13.2B | $12.2B | ||
| Q3 25 | $13.2B | $12.1B | ||
| Q2 25 | $13.2B | $12.4B | ||
| Q1 25 | $13.2B | $12.4B | ||
| Q4 24 | $12.9B | $12.4B | ||
| Q3 24 | $12.6B | $12.8B | ||
| Q2 24 | $12.5B | $13.4B | ||
| Q1 24 | $12.9B | $13.4B |
负债/权益比ESSRVTY
| Q4 25 | — | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 12.53× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ESSRVTY
| Q4 25 | $1.1B | $182.0M | ||
| Q3 25 | $342.6M | $138.5M | ||
| Q2 25 | $216.1M | $134.3M | ||
| Q1 25 | $281.5M | $128.2M | ||
| Q4 24 | $1.1B | $174.2M | ||
| Q3 24 | $316.2M | $147.9M | ||
| Q2 24 | $218.9M | $158.6M | ||
| Q1 24 | $314.9M | $147.6M |
自由现金流ESSRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率ESSRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度ESSRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率ESSRVTY
| Q4 25 | 12.53× | 1.85× | ||
| Q3 25 | 1.98× | 2.97× | ||
| Q2 25 | 0.93× | 2.49× | ||
| Q1 25 | 1.32× | 3.03× | ||
| Q4 24 | 3.54× | 1.84× | ||
| Q3 24 | 2.52× | 1.57× | ||
| Q2 24 | 2.21× | 2.87× | ||
| Q1 24 | 1.10× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESS
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
